Hong Kong · Delayed Price · Currency is HKD Qyuns Therapeutics Company Description
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China.
Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which is in Phase III clinical trial for the treatment of prurigo nodularis.
The company also commercializes QX001S, which is an IL-12/L-23p49 inhibitor for psoriasis under the SAILEXIN brand.
In addition, it develops, manufactures, and commercializes QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD; QX004N, an IL-23p19 inhibitor in Phase II clinical trial to treat psoriasis and Crohn’s disease; QX013N, a humanized IgG1 mAb targeting c-kit; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial for the treatment of systemic lupus erythematosus; QX007N, a humanized IgG1 mAb targeting IL-33 for the treatment of moderate-to-severe COPD and asthma; and QX010N, an IL-31R inhibitor for the treatment of pruritus.
Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services.
Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 339 |
| CEO | Jiwan Qiu |
Contact Details
Address: Building 1 Taizhou China | |
| Phone | 86 523 8027 6311 |
| Website | qyuns.net |
Stock Details
| Ticker Symbol | 2509 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000069W9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jiwan Qiu | GM and Chairman of the Board |
| Yiliang Wu | Executive Director and Executive Deputy GM of Cellularforce |
| Weidong Lin | Deputy GM and Executive Director |
| Min Fang | Deputy General Manager |
| Yanbao Hu | Board Secretary and Joint Company Secretary |
| King Yin Tang | Joint Company Secretary |